IRVINE, Calif., Jan. 5, 2015 /PRNewswire/ -- TiaLinx, Inc., the developer of the Viper60™ technology, announced the launch of its new product line, the AR60-A. The AR60-A is a laptop size, portable, and non-contact screening system designed to detect abnormal tissues in female breasts. The technology detects the different electrical properties of abnormal cells as compared to the healthy ones. In contrast to X-Rays, which accumulate radiation in the body, the 60GHz scanning technology does not emit ionizing radiation, making the AR60-A a quintessential technology for the medical field.
The wafer-scale beamforming technology of TiaLinx and its patented planar antenna arrays enable scanning with fine lateral resolution, ultimately enhancing the detection and imaging of small cell clusters. Moreover, signal processing with polarization capabilities enhances the suppression of scattering, while the advanced ultra-wideband (UWB) transmitter and receiver provide the user with the ability to obtain high depth resolution for sharp images.
The Cancer Treatment Center of America (CTCA) reports that the cancer survival rate declines from 95% to 26% between the initial diagnosis and five years after being diagnosed. Additionally, according to Life Science Industry Research's market projections, the worldwide breast cancer screening population is expected to be just short of 250 million individuals by 2018. Furthermore, the global market for breast cancer diagnostic and drug technologies approximated $22.3 billion in 2014. "The demand for the development of an affordable device for early-stage breast cancer detection by over 210,000 primary care physicians in the United States, and significantly more internationally, has been a key driver behind the introduction of the AR-60A," commented Dr. Fred Mohamadi, Founder and President of TiaLinx.
About TiaLinx, Inc.
TiaLinx, Inc. is a privately held company with 100% American ownership. The Company develops advanced electronic modules with very small form factors, highly integrated functionality, and advanced performance for a wide range of medical applications. Utilizing its 62 granted and many more pending patent applications, specifically related to the detection of abnormal tissues and monitoring breathing remotely, the Company is uniquely positioned to provide small footprint, portable, and low-cost medical instruments.
For further information, please visit the Company's website at www.TiaLinx.com.
Press Release Contact: Judy Deban through: Email; or (949) 334-3048
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tialinx-inc-announces-the-development-of-its-ar60-a-scanner-technology-to-detect-abnormal-breast-cell-clusters-300015061.html
SOURCE TiaLinx, Inc.